Biotech Archives - Page 690 of 733

1 minute read

Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, At Six-Month Timepoint Following Booster With ARCT-154 COVID-19 Vaccine

August 18, 8:02 AM

New clinical data demonstrate high and sustained geometric mean fold rises (GMFR) in neutralizing antibodies against all evaluated Omicron variants Six months after booster dose of ARCT-154: BA.1: GMFR = 22 to 52;

ARCT

2 minute read

Science 37 And Syapse Partner To Enable Faster Patient Enrollment In Oncology Clinical Trials

By Benzinga Newsdesk

August 18, 7:55 AM

Science 37 Holdings, Inc. (NASDAQ:SNCE), the Agile Clinical Trial Operating System™, and Syapse®, a leading real-world evidence company, today announced a partnership to deploy proprietary real-world data

SNCE

2 minute read

Jazz Pharmaceuticals Announces Initiation Of Phase 3 Trial Evaluating Epidiolex/Epidyolex For Patients With Epilepsy With Myoclonic-Atonic Seizures

By Bill Haddad

August 18, 7:32 AM

Trial is the first randomized, controlled clinical trial evaluating cannabidiol to treat children and adolescents living with a developmental and epileptic encephalopathy known as Epilepsy with

JAZZ

2 minute read

BioCryst Announces Approval Of ORLADEYO In Saudi Arabia

By Benzinga Newsdesk

August 18, 7:12 AM

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Saudi Food and Drug Authority (SFDA) has approved oral, once-daily ORLADEYO® (berotralstat) to prevent attacks of hereditary

BCRX

2 minute read

BD Launches First-in-Human Trial Of Sirolimus Drug-Coated Balloon To Expand Treatment Options For Peripheral Arterial Disease

By Benzinga Newsdesk

August 18, 6:36 AM

BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, has announced the start of enrollment in a first-in-human trial of a peripheral sirolimus drug-coated balloon (DCB). BD is a

BDX

2 minute read

Why This Analyst Sees A 51% Return On This Cathie Wood-Favored Biotech Stock

By AJ Fabino

August 17, 6:33 PM

Biotech stocks have the potential for huge gains if a product or drug is deemed effective and safe, but investing in the shares of those companies can be volatile.

ARKK

2 minute read

Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

August 17, 6:33 PM

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat…

BLUE

3 minute read

Independent Study Shows Cue Health’s Molecular COVID-19 Test is as Accurate as Lab-Based PCR Test

By Benzinga Newsdesk

August 17, 4:23 PM

SAN DIEGO, Calif., Aug. 17, 2022 /PRNewswire/ -- Cue Health Inc. ("Cue") (NASDAQ: HLTH) announced today the preprint publication of an independent clinical study - the largest of itsSAN DIEGO, Calif., Aug. 17, 2022 /PRNewswire/ -- Cue Health Inc.

HLTH

1 minute read

This Analyst Cuts I-Mab’s Price Target By 43%

By Vandana Singh

August 17, 3:24 PM

I-Mab (NASDAQ: IMAB) reported significant changes to the company's collaboration on developing CD47 targeting agents.

ABBV

1 minute read

Bluebird’s Gene Therapy Scores US Approval For Genetic Blood Disorder, Probably The Most Expensive

By Vandana Singh

August 17, 3:16 PM

The FDA has approved Bluebird bio Inc’s (NASDAQ:BLUE) Zynteglo (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy custom-designed for…

BLUE